Literature DB >> 21415408

Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.

Christine E Seidman1, J G Seidman.   

Abstract

This review provides an historical and personal perspective on the discovery of genetic causes for hypertrophic cardiomyopathy (HCM). Extraordinary insights by physicians who initially detailed remarkable and varied manifestations of the disorder, collaboration among multidisciplinary teams with skills in clinical diagnostics and molecular genetics, and hard work by scores of trainees solved the etiologic riddle of HCM and unexpectedly demonstrated mutations in sarcomere protein genes as the cause of disease. In addition to celebrating 20 years of genetic research in HCM, this article serves as an introductory overview to a thematic review series that will present contemporary advances in the field of hypertrophic heart disease. Through the continued application of advances in genetic methodologies, combined with biochemical and biophysical analyses of the consequences of human mutations, fundamental knowledge about HCM and sarcomere biology has emerged. Expanding research to elucidate the mechanisms by which subtle genetic variation in contractile proteins remodel the human heart remains an exciting opportunity, one with considerable promise to provide new strategies to limit or even prevent HCM pathogenesis.

Entities:  

Mesh:

Year:  2011        PMID: 21415408      PMCID: PMC3072749          DOI: 10.1161/CIRCRESAHA.110.223834

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  92 in total

1.  Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy.

Authors:  Tetsuo Konno; Dan Chen; Libin Wang; Hiroko Wakimoto; Polakit Teekakirikul; Matthew Nayor; Masataka Kawana; Seda Eminaga; Joshua M Gorham; Kumar Pandya; Oliver Smithies; Francisco J Naya; Eric N Olson; J G Seidman; Christine E Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis.

Authors:  R BROCK
Journal:  Guys Hosp Rep       Date:  1957

3.  Expression of human beta-myosin heavy chain fragments in Escherichia coli; localization of actin interfaces on cardiac myosin.

Authors:  P Eldin; M Le Cunff; K W Diederich; T Jaenicke; B Cornillon; D Mornet; H P Vosberg; J J Léger
Journal:  J Muscle Res Cell Motil       Date:  1990-10       Impact factor: 2.698

4.  Hypertrophic cardiomyopathy: the great masquerader. Clinical conference from the Cardiology Branch of the National Heart, Lung, and Blood Institute, Bethesda, Md.

Authors:  B J Maron; J S Gottdiener; R E Goldstein; S E Epstein
Journal:  Chest       Date:  1978-12       Impact factor: 9.410

5.  Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.

Authors:  Polakit Teekakirikul; Seda Eminaga; Okan Toka; Ronny Alcalai; Libin Wang; Hiroko Wakimoto; Matthew Nayor; Tetsuo Konno; Joshua M Gorham; Cordula M Wolf; Jae B Kim; Joachim P Schmitt; Jefferey D Molkentin; Russell A Norris; Andrew M Tager; Stanley R Hoffman; Roger R Markwald; Christine E Seidman; Jonathan G Seidman
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

6.  Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin.

Authors:  J Martijn Bos; Rainer N Poley; Melissa Ny; David J Tester; Xiaolei Xu; Matteo Vatta; Jeffrey A Towbin; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Mol Genet Metab       Date:  2005-12-13       Impact factor: 4.797

7.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction.

Authors:  H L Sweeney; A J Straceski; L A Leinwand; B A Tikunov; L Faust
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

8.  Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker.

Authors:  L C Tsui; M Buchwald; D Barker; J C Braman; R Knowlton; J W Schumm; H Eiberg; J Mohr; D Kennedy; N Plavsic
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

9.  A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia.

Authors:  Perundurai S Dhandapany; Sakthivel Sadayappan; Yali Xue; Gareth T Powell; Deepa Selvi Rani; Prathiba Nallari; Taranjit Singh Rai; Madhu Khullar; Pedro Soares; Ajay Bahl; Jagan Mohan Tharkan; Pradeep Vaideeswar; Andiappan Rathinavel; Calambur Narasimhan; Dharma Rakshak Ayapati; Qasim Ayub; S Qasim Mehdi; Stephen Oppenheimer; Martin B Richards; Alkes L Price; Nick Patterson; David Reich; Lalji Singh; Chris Tyler-Smith; Kumarasamy Thangaraj
Journal:  Nat Genet       Date:  2009-01-18       Impact factor: 38.330

10.  Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy.

Authors:  G Bonne; L Carrier; J Bercovici; C Cruaud; P Richard; B Hainque; M Gautel; S Labeit; M James; J Beckmann; J Weissenbach; H P Vosberg; M Fiszman; M Komajda; K Schwartz
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

View more
  97 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

Review 2.  Multi-scale computational models of familial hypertrophic cardiomyopathy: genotype to phenotype.

Authors:  Stuart G Campbell; Andrew D McCulloch
Journal:  J R Soc Interface       Date:  2011-08-10       Impact factor: 4.118

Review 3.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

Review 4.  Matricellular proteins and biomaterials.

Authors:  Aaron H Morris; Themis R Kyriakides
Journal:  Matrix Biol       Date:  2014-03-20       Impact factor: 11.583

5.  Left Ventricular Hypertrophy in Rhesus Macaques (Macaca mulatta) at the California National Primate Research Center (1992-2014).

Authors:  J Rachel Reader; Don R Canfield; Jennifer F Lane; Sreetharan Kanthaswamy; Amir Ardeshir; A Mark Allen; Ross P Tarara
Journal:  Comp Med       Date:  2016-04       Impact factor: 0.982

6.  The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.

Authors:  Carolyn Y Ho; John J V McMurray; Allison L Cirino; Steven D Colan; Sharlene M Day; Akshay S Desai; Steven E Lipshultz; Calum A MacRae; Ling Shi; Scott D Solomon; E John Orav; Eugene Braunwald
Journal:  Am Heart J       Date:  2017-02-16       Impact factor: 4.749

7.  Myosin Rod Hypophosphorylation and CB Kinetics in Papillary Muscles from a TnC-A8V KI Mouse Model.

Authors:  Masataka Kawai; Jamie R Johnston; Tarek Karam; Li Wang; Rakesh K Singh; Jose R Pinto
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

8.  Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality.

Authors:  Ali J Marian
Journal:  Circ Res       Date:  2014-01-17       Impact factor: 17.367

9.  Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy.

Authors:  Takeharu Hayashi; Kousuke Tanimoto; Kayoko Hirayama-Yamada; Etsuko Tsuda; Mamoru Ayusawa; Shinichi Nunoda; Akira Hosaki; Akinori Kimura
Journal:  J Hum Genet       Date:  2018-06-15       Impact factor: 3.172

10.  Significance of troponin dynamics for Ca2+-mediated regulation of contraction and inherited cardiomyopathy.

Authors:  Devanand Kowlessur; Larry S Tobacman
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.